Sheppard Mullin advised WestPark Capital, Inc. and WallchBeth Capital LLC on the deal. Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) (Nasdaq: Common stock – LIXT;…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
